EUVIMEDEUVIMED entdecken
Multizentrische Studie

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWP

Ali Bazarbachi iD, Jacques-Emmanuel Galimard, Iman Abou Dalle iD, Gérard Socié, Jurjen Versluis, Depei Wu, Matthias Eder, Hélène Labussière-Wallet, Ibrahim Yakoub-Agha, Johan Maertens, Edouard Forcade, Tobias Gedde-Dahl und 8 weitere

American Journal of Hematology · 2025-08 · 100 (8) · 1374-1386

DOI: 10.1002/ajh.27726 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 30.05.2025. Verfasst von Ali Bazarbachi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Chromosome Aberrations. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: European Society for Blood and Marrow Transplantation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

According to the European LeukemiaNet (ELN) 2022 classification, acute myeloid leukemia (AML) patients with intermediate or adverse risk are offered allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in first remission. In this EBMT study, we included 1735 adult AML patients with ELN‐2022 adverse‐risk cytogenetics allografted between 2010 and 2022 in first remission (67% de novo AML, median age 56 years). Eleven non‐overlapping adverse‐risk cytogenetics groups were defined. The five most frequent were: Group 1 [ n = 394; monosomy 17 or abn(17p); 2‐year leukemia‐free survival (LFS) 22%, and overall survival (OS) 25%]; Group 2 [ n = 313; complex karyotype (CK) involving monosomy 5, monosomy 7, or del(5q) without monosomy 17 or abn(17p); LFS 27%, OS 37%]; Group 3 [ n = 201; monosomy 5, monosomy 7, or del(5q) without CK and without monosomy 17 or abn(17p); LFS: 55%, OS: 63%]; Group 4 [ n = 256; CK without monosomal karyotype (MK) or adverse additional cytogenetic abnormalities (ACA); LFS 50%, OS 61%]; Group 5 [ n = 213; t(v, 11q23) without adverse ACA; LFS 50%, OS 59%]. In multivariable analysis, compared to CK without adverse ACA, LFS was negatively affected by monosomy 17 or 17p abnormalities, monosomy 5, 7, or del(5q) in the presence of CK, and t(8;16). In conclusion, this study revealed a very poor outcome of allografted AML patients with monosomy 17 or 17p abnormalities or CK involving monosomy 5, monosomy 7, and del5q. Outcomes were relatively favorable for most other ELN 2022 adverse categories, including CK with or without MK other than 5, 7, and 17, indicating that allo‐HSCT can overcome their poor outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationChromosome AberrationsHumansMiddle AgedMaleFemaleAdultAgedAdolescentRemission InductionYoung AdultChromosome DeletionAllograftsTransplantation, HomologousMonosomyDisease-Free SurvivalChromosomes, Human, Pair 7Chromosomes, Human, Pair 17

Stichwörter der Autor:innen

AMLELN 2022 risk stratificationallogeneic hematopoietic stem cell transplantation (allo‐HSCT)complex karyotypecytogenetic risk groups

Autor:innen und Institutionen

  • Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
  • EBMT Paris Study Unit, Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France.
  • Saint-Louis Hospital, BMT Unit, Paris, France.
  • Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • First Affiliated Hospital of Soochow University, Suzhou, China.
  • Hannover Medical School, Hannover, Germany.

ORCID-Profile: Ali Bazarbachi, Iman Abou Dalle, Jordi Esteve

Förderung

  • European Society for Blood and Marrow Transplantation

Zitieren

APA

Bazarbachi, A., Galimard, J. E., Dalle, I. A., Socié, G., Versluis, J., Wu, D., Eder, M., Labussière-Wallet, H., Yakoub-Agha, I., Maertens, J., Forcade, E., Gedde-Dahl, T., Choi, G., Castilla-Llorente, C., Baron, F., Brissot, E., Esteve, J., Nagler, A., Mohty, M., & Ciceri, F. (2025). Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWP. American Journal of Hematology, 100(8), 1374-1386. https://doi.org/10.1002/ajh.27726

Vancouver

Bazarbachi A, Galimard JE, Dalle IA, Socié G, Versluis J, Wu D, et al. Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWP. American Journal of Hematology. 2025;100(8):1374-1386. doi:10.1002/ajh.27726

BibTeX
@article{Bazarbachi2025,
  author = {Bazarbachi, Ali and Galimard, Jacques-Emmanuel and Dalle, Iman Abou and Socié, Gérard and Versluis, Jurjen and Wu, Depei and Eder, Matthias and Labussière-Wallet, Hélène and Yakoub-Agha, Ibrahim and Maertens, Johan and Forcade, Edouard and Gedde-Dahl, Tobias and Choi, Goda and Castilla-Llorente, Cristina and Baron, Frederic and Brissot, Eolia and Esteve, Jordi and Nagler, Arnon and Mohty, Mohamad and Ciceri, Fabio},
  title = {Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWP},
  journal = {American Journal of Hematology},
  year = {2025},
  volume = {100},
  number = {8},
  pages = {1374--1386},
  doi = {10.1002/ajh.27726}
}
Kostenlos starten →